Literature DB >> 7684876

Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1.

H Soudeyns1, R Geleziunas, G Shyamala, J Hiscott, M A Wainberg.   

Abstract

We have shown that (HIV-1) replication can be regulated by interaction between glucocorticoid hormones and the viral genome; treatment of acutely infected lymphoid and monocytoid cell lines with cortisol and dexamethasone increased HIV-1 production in culture. The magnitude of this response correlated with glucocorticoid receptor (GR) and GR message in responder and non-responder cell lines. Furthermore, treatment of each of two HIV-infected cell lines with glucocorticoids led to enhancement of HIV-1 gene expression. We have identified a novel intragenic glucocorticoid response element (GRE) within the genome of HIV-1 at position +5002 in the vif open reading frame, as well as a second potential GRE, previously identified by other researchers at position -257 in the HIV-1 negative regulatory element (LTR-NRE). Our data indicate that only the motif at position +5002 represents a true GRE that confers glucocorticoid inducibility to a MMTV-luciferase reporter gene construct. The GRE located at -257 lacked significant functional activity in its native configuration in that it could bind GR but did not transactivate reporter gene constructs. However, this sequence was able to impart glucocorticoid inducibility when inverted or dimerized. These results suggest that as in the case of other retroviruses, HIV-1 has evolved to interface with the GR signal transduction pathway to gain replicative advantage in target cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684876     DOI: 10.1006/viro.1993.1317

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  19 in total

1.  Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest.

Authors:  M P Sherman; C M de Noronha; D Pearce; W C Greene
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Identification of sequences downstream of the primer binding site that are important for efficient replication of human immunodeficiency virus type 1.

Authors:  X Li; C Liang; Y Quan; R Chandok; M Laughrea; M A Parniak; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.

Authors:  Harriet Mayanja-Kizza; Edward Jones-Lopez; Alphonse Okwera; Robert S Wallis; Jerrold J Ellner; Roy D Mugerwa; Christopher C Whalen
Journal:  J Infect Dis       Date:  2005-02-08       Impact factor: 5.226

Review 4.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

5.  Dexamethasone and mifepristone increase retroviral infectivity through different mechanisms.

Authors:  Victor Solodushko; Vira Bitko; Brian Fouty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-06-26       Impact factor: 5.464

Review 6.  Oral candidiasis, HIV, and saliva glucocorticoids.

Authors:  C O Enwonwu; V I Meeks
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

7.  Characterisation of the long terminal repeat regions of South African human immunodeficiency virus type 1 isolates.

Authors:  G M Hunt; D Johnson; C T Tiemesse
Journal:  Virus Genes       Date:  2001       Impact factor: 2.332

8.  MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data.

Authors:  K Quandt; K Frech; H Karas; E Wingender; T Werner
Journal:  Nucleic Acids Res       Date:  1995-12-11       Impact factor: 16.971

9.  Identification of a novel cell-type and context specific enhancer within the negative regulatory element of the human immunodeficiency virus type 1 long terminal repeat.

Authors:  S K Sikder; D Mitra; J Laurence
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

10.  Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms.

Authors:  Richard P H Huijbregts; E Scott Helton; Katherine G Michel; Steffanie Sabbaj; Holly E Richter; Paul A Goepfert; Zdenek Hel
Journal:  Endocrinology       Date:  2013-01-25       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.